Early anticoagulation therapy for severe burns complicated by inhalation injury in a rabbit model

Mol Med Rep. 2017 Nov;16(5):7375-7381. doi: 10.3892/mmr.2017.7537. Epub 2017 Sep 20.

Abstract

The aim of the present study was to determine the effects of early anticoagulation treatment on severe burns complicated by inhalation injury in a rabbit model. Under anesthetization, an electrical burns instrument (100˚C) was used to scald the backs of rabbits for 15 sec, which established a 30% III severe burns model. Treatment of the rabbits with early anticoagulation effectively improved the severe burns complicated by inhalation injury‑induced lung injury, reduced PaO2, PaCO2 and SPO2 levels, suppressed the expression of tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6, and increased the activity of IL‑10. In addition, it was found that early anticoagulation treatment effectively suppressed the activities of caspase‑3 and caspase‑9, upregulated the protein expression of vascular endothelial growth factor (VEGF) and decreased the protein expression of protease‑activated receptor 1 (PAR1) in the severe burns model. It was concluded that early anticoagulation treatment affected the severe burns complicated by inhalation injury in a rabbit model through the upregulation of VEGF and downregulation of PAR1 signaling pathways. Thus, early anticoagulation is a potential therapeutic option for severe burns complicated by inhalation injury.

MeSH terms

  • Animals
  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use*
  • Antithrombin III / pharmacology
  • Antithrombin III / therapeutic use
  • Caspase 3 / metabolism
  • Caspase 9 / metabolism
  • Central Venous Pressure / drug effects
  • Disease Models, Animal
  • Heparin / pharmacology
  • Heparin / therapeutic use
  • Interleukin-10 / metabolism
  • Interleukin-1beta / metabolism
  • Interleukin-6 / metabolism
  • Lung / drug effects
  • Lung / metabolism
  • Lung / pathology
  • Rabbits
  • Receptor, PAR-1 / metabolism
  • Severity of Illness Index
  • Smoke Inhalation Injury / drug therapy*
  • Smoke Inhalation Injury / metabolism
  • Smoke Inhalation Injury / pathology
  • Transcription Factor RelA / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Anticoagulants
  • Interleukin-1beta
  • Interleukin-6
  • Receptor, PAR-1
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Vascular Endothelial Growth Factor A
  • Interleukin-10
  • Antithrombin III
  • Heparin
  • Caspase 3
  • Caspase 9